



RESEARCH NOTE

# SNP-SNP interactions as risk factors for aggressive prostate cancer [version 1; referees: 2 approved]

Venkatesh Vaidyanathan <sup>1,2</sup>, Vijay Naidu<sup>3</sup>, Nishi Karunasinghe<sup>2</sup>, Anower Javed<sup>4</sup>, Radha Pallati<sup>1</sup>, Gareth Marlow<sup>5</sup>, Lynnette R. Ferguson<sup>1,2</sup>

<sup>1</sup>Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland, New Zealand

<sup>2</sup>Auckland Cancer Society Research Centre, Auckland, New Zealand

<sup>3</sup>School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland, New Zealand

<sup>4</sup>Department of Molecular Medicine and Pathology, FM & HS, University of Auckland, Auckland, New Zealand

<sup>5</sup>Experimental Cancer Medicine Centre, Cardiff University, Cardiff, UK

**v1** First published: 03 May 2017, 6:621 (doi: [10.12688/f1000research.11027.1](https://doi.org/10.12688/f1000research.11027.1))  
 Latest published: 03 May 2017, 6:621 (doi: [10.12688/f1000research.11027.1](https://doi.org/10.12688/f1000research.11027.1))

**Abstract**

Prostate cancer (PCa) is one of the most significant male health concerns worldwide. Single nucleotide polymorphisms (SNPs) are becoming increasingly strong candidate biomarkers for identifying susceptibility to PCa. We identified a number of SNPs reported in genome-wide association analyses (GWAS) as risk factors for aggressive PCa in various European populations, and then defined SNP-SNP interactions, using PLINK software, with nucleic acid samples from a New Zealand cohort. We used this approach to find a gene x environment marker for aggressive PCa, as although statistically gene x environment interactions can be adjusted for, it is highly impossible in practicality, and thus must be incorporated in the search for a reliable biomarker for PCa. We found two intronic SNPs statistically significantly interacting with each other as a risk for aggressive prostate cancer on being compared to healthy controls in a New Zealand population.

**Open Peer Review**

Referee Status:

	Invited Referees	
	1	2
<b>version 1</b> published 03 May 2017	 report	 report
<p>1 <b>Syed Muhammad Shahid</b>, University of Karachi Pakistan</p> <p>2 <b>Yog Raj Ahuja</b>, Vasavi Medical &amp; Research Centre India, <b>Zeenath Jehan</b>, Vasavi Medical &amp; Research Centre India</p>		

**Discuss this article**

Comments (0)

**Corresponding author:** Venkatesh Vaidyanathan ([v.vaidyanathan@auckland.ac.nz](mailto:v.vaidyanathan@auckland.ac.nz))

**Competing interests:** No competing interests were disclosed.

**How to cite this article:** Vaidyanathan V, Naidu V, Karunasinghe N *et al.* **SNP-SNP interactions as risk factors for aggressive prostate cancer [version 1; referees: 2 approved]** *F1000Research* 2017, 6:621 (doi: [10.12688/f1000research.11027.1](https://doi.org/10.12688/f1000research.11027.1))

**Copyright:** © 2017 Vaidyanathan V *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](https://creativecommons.org/licenses/by/4.0/) (CC0 1.0 Public domain dedication).

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**First published:** 03 May 2017, 6:621 (doi: [10.12688/f1000research.11027.1](https://doi.org/10.12688/f1000research.11027.1))

## Introduction

Prostate cancer (PCa) is highly prevalent, and around 1 in 6 patients are at risk of developing the aggressive form of the disease<sup>1</sup>. It has become one of the most significant male health concerns worldwide<sup>2</sup>. An individual is diagnosed as having high-risk or aggressive PCa based on the classification by the American Urological Association<sup>3</sup>, when the clinical T stage  $\geq$ cT2c, and/or the Gleason score  $\geq$ 8, and/or the serum prostate serum antigen (PSA) level  $>20\text{ng/ml}$ <sup>4</sup>.

Although a hereditary aspect is well known for this disease<sup>5</sup>, various studies have also shown that genetic interactions with biological and behavioral factors play an important role in the overall risk and prognosis of PCa<sup>6-8</sup>. Variations in the genome are a major contributor to the differences in disease susceptibility amongst individuals<sup>9</sup>. Single nucleotide polymorphisms (SNPs) are the most commonly identified variations in a genome.

Analysing the role of SNP-SNP interactions and epistasis<sup>10</sup> is very appealing among researchers working on risk factors for various cancers<sup>11-13</sup>, including prostate cancer<sup>14</sup>. Here we have identified a SNP-SNP interaction as a risk factor for aggressive PCa, by comparing the data generated after carrying out SNP genotyping using the SEQUENOM MassARRAY iPLEX<sup>®</sup> assay, and the TaqMan<sup>®</sup> assay (depending on the gene of interest) from the DNA extracted from blood samples. These samples were taken from a New Zealand cohort of men with self-reported European ethnicity that have been clinically diagnosed with aggressive and non-aggressive PCa, and healthy controls with no reported symptoms of the disease. Symptoms include increased urination during night time along with a frequent urge to urinate problems maintaining a steady flow of urine, hematuria and dysuria<sup>15</sup>. Our results indicate a strong influence of gene x environment interaction in overall gene expression and epistasis.

## Methods

### Study population

Patients with a clinically established diagnosis of PCa (aggressive and non-aggressive) from the Auckland Regional Urology Registry (Auckland, Middlemore, and North Shore hospitals), and certain private practices in the Waikato region of New Zealand were sent invitations along with the written consent forms to participate in this study between the years 2006 and 2014. Eventually, a total of 254 patients with various grades of PCa voluntarily participated in our study after providing us with written informed consent. (Ethics reference NTY05/06/037 by Northern B Ethics Committee, New Zealand, previously Northern Y Ethics Committee, New Zealand). Additionally, 369 males from the Auckland region of New Zealand with no reported symptoms of PCa were considered as healthy controls for this study (Ethics reference NTY/06/07/AM04 by Northern B Ethics Committee, New Zealand, previously Northern Y Ethics Committee, New Zealand), recruited by advertising in and around the University of Auckland. Written informed consent for participation in the study was also obtained from the male healthy controls.

Each individual participating in this study completed a demographic and lifestyle questionnaire. Because of the influence of age in this disease<sup>16</sup>, care was taken to invite men to participate in this study that were between the ages of 40 to 90 years at the time of diagnosis for patients with PCa, and at the time of recruitment for healthy controls. (Dataset 1<sup>17</sup>). The average age of men with aggressive PCa was calculated to be 66 years, 67 years for men with non-aggressive PCa and 58 years for healthy controls.

### Collection and processing of blood samples

Patient blood samples were collected at respective outpatient clinics at the Auckland, North Shore and Counties Manukau Hospitals, New Zealand. The blood samples of healthy controls were collected at the Faculty of Medical and Health Sciences, the University of Auckland, New Zealand and the New Zealand Blood Bank, Great South Road Centre, Epsom, Auckland New Zealand.

Blood samples from each participant were collected in Vacutainer<sup>®</sup> tubes (Becton Dickinson) containing EDTA by a trained phlebotomist. DNA was extracted using a QIAamp genomic DNA kit (Qiagen, Hilden, Germany) following the manufacturer's protocol, with the aid of a fully automated QIAcube (Qiagen, Hilden, Germany). The DNA samples were diluted to  $5.0\text{ng}/\mu\text{l}$  as per requirements of the SEQUENOM MassARRAY iPLEX<sup>®</sup> assay protocol.

### Selection and genotyping of SNPs

136 SNPs, located in 66 genes and some undefined chromosomal locations were identified by a thorough literature search of GWAS for both aggressive PCa and PCa. Care was taken to select SNPs that were identified as significantly associated with risks for PCa and aggressive PCa in European populations only. Research papers were only considered if published in and after the year 2000, in order to be in concordance with the current trends in PCa research. The final SNPs selected to be genotyped were at the research team's discretion, either by SEQUENOM MassARRAY iPLEX<sup>®</sup> assay or by TaqMan<sup>®</sup> SNP genotyping assay, as discussed in Vaidyanathan *et al.*, 2017<sup>18</sup>.

SNP genotyping by SEQUENOM MassARRAY iPLEX<sup>®</sup> assay for the candidate SNPs was carried out in the Auckland UniServices Sequenom Facility at The Liggins Institute, Auckland, and AgResearch Limited, Mosgiel, New Zealand, using a custom-designed multiplex gene panel and iPlex chemistry. The genotype calling was carried out by using the standard post-processing calling parameters from the SEQUENOM Type 4.0 software.

SNP genotyping using the TaqMan<sup>®</sup> SNP genotyping (Applied Biosystems, ABI) was carried out on a panel of genes that failed to be genotyped using the SEQUENOM MassARRAY iPLEX<sup>®</sup> assay. The primers used were either obtained pre-designed from ABI or were custom-made using Assay-by-Design service by ABI, and the protocol provided by the manufacturers was followed<sup>7,18-20</sup>.

## Statistical analysis

26 SNPs were removed for being in linkage, and a further 5 SNPs were removed for failing the Hardy-Weinberg Equilibrium (HWE) in the healthy controls, thereby reducing the total SNPs analyzed to 105 (colour coded in [Dataset 1](#)<sup>17</sup>). SNPs that failed the HWE in patients with PCa were still considered for analysis, as the SNPs may have failed to be in equilibrium in the patient population due to the influence of the risk allele and hence should not be ignored from a case-control study like ours<sup>21,22</sup>. The statistical significance was set to  $p \leq 0.0001$ <sup>23</sup>.

Analysis of the data for SNP-SNP interactions associated with aggressive PCa was carried out using PLINK software version 1.07<sup>18,23</sup>. PLINK's clustering approach, identical-by-state (IBS) clustering, is based on pairing up the SNPs based on similarity of genetic identity. This IBS clustering is used in order to test if the SNPs of two individuals belong to the same population or not<sup>18</sup>. Following this stratification, we performed a standard case-control association test using the Cochran-Mantel-Haenszel test (1 degree of freedom) to analyse the SNP-disease association that is conditional on the clustering<sup>18</sup>. The slower '--epistasis' command was used to test for epistasis using logistic regression<sup>23</sup>. It is the most accurate test to define SNP-SNP interactions using PLINK<sup>23</sup>.

## Results

[Table 1](#) shows the statistically significant SNP-SNP interaction discovered in patients with aggressive PCa when compared to healthy controls. The results obtained for other categorical analyses are not discussed here, as they were not statistically significant in our study and have been mentioned in Supplementary Table 2. The SNP rs2121875, an intronic SNP present in chromosomal position 5p12 near the fibroblast growth factor 10 (*FGF10*) gene<sup>24</sup>, has been identified to be associated with the SNP rs4809960, an intronic SNP present in chromosomal position 20q13 near the gene cytochrome P450 family 24 subfamily A member 1 (*CYP24A1*)<sup>25</sup>, such that the latter SNP raises the odds of having the prior.

### Dataset 1. Raw data from the current study

<http://dx.doi.org/10.5256/f1000research.11027.d158605>

### Dataset 2. Epistasis results after analysis of the data for SNP-SNP interactions

<http://dx.doi.org/10.5256/f1000research.11027.d158606>

## Discussion

Epistatic effects that are crucial to define various biologically-intuitive models of interaction between two SNPs have already been observed in a variety of species<sup>11</sup>. We believe this is the first study on SNP-SNP interactions associated with aggressive PCa carried out with patients from a New Zealand population.

The SNP rs4809960 in the gene *CYP24A1* has been reported by Holt *et al.*, (2010) to be associated with prostate cancer-specific mortality, and was not evolutionarily conserved<sup>25</sup>. It was also found to have an effect on the body mass index (BMI), but due to a small sample size the hazard ratios for the BMI strata were not considered reliable enough to be reported<sup>25</sup>. The protein encoded by *CYP24A1* initiates the degradation of the physiologically active form of Vitamin D3 (VD3)<sup>26</sup>. VD3 is an important hormone that is actively involved in regulating cell proliferation in the prostate, and has also been identified to have increased expression in PCa cell lines<sup>27</sup>. It is well established that, with ageing, the skin cannot synthesize VD3 as effectively as desirable and the kidney's ability to convert VD3 to its active form decreases<sup>28</sup>. This is of relevance because PCa has always been considered as a disease of elderly men<sup>29</sup> who have had less exposure to sunlight and thereby Vitamin D3<sup>30</sup>. It is even more intriguing for the other epistatic SNP to be identified in *FGF10*.

According to Paul *et al.* (2013), during mesenchymal development, eFGF10 protein can trigger PCa development through increased androgen receptor expression in the neoplastic epithelium<sup>31</sup>. It is also worthy to mention that FGF10 is closest to FGF7 based on its evolutionary history<sup>32</sup>, and according to Emoto *et al.* (1997), is suggested to have no activity for fibroblasts<sup>32</sup>. We do not agree with this, because fibroblasts in certain organs, senesce due to aging<sup>33</sup>, and can promote tumour invasion<sup>34</sup>. This logical progression of ageing-led senescence and promotion of tumour invasion holds true for ageing and risk of aggressive PCa<sup>16</sup> as well.

We suggest that the intronic SNP rs2121875 in the gene *FGF10* may be causing alterations in gene expression, perhaps due to the prevalent external/environmental conditions in the elderly men with PCa. Our theory is based on the recent discovery in a study by Zhang *et al.* (2007) that even intronic SNPs (such as the ones identified in *FGF10* and *CYP24A1*) can change the outcome and usage of exons<sup>35,36</sup>. This unique and novel epistatic finding emphasizes the fact that intronic SNPs (and SNP-SNP interactions) can also have a significant effect on the risk of diseases such as aggressive PCa, and need to be investigated further.

**Table 1. Statistically significant SNP-SNP interactions discovered in patients with aggressive PCa when compared to healthy controls.**

CHR1: chromosome of first SNP, SNP1: Identifier for first SNP, CHR2: Chromosome of second SNP, SNP2: Identifier for second SNP, OR\_INT: Odds ratio for interaction, STAT: Chi-square statistic 1df, p: Asymptotic p-value.

CHR1	SNP1	CHR2	SNP2	OR_INT	STAT	P
5p12	rs2121875	20q13	rs4809960	2.918	15.77	7.15E-05

## Data availability

Dataset 1: Raw data from the current study. DOI, [10.5256/f1000research.11027.d158605](https://doi.org/10.5256/f1000research.11027.d158605)<sup>17</sup>

Dataset 2: Epistasis results after analysis of the data for SNP-SNP interactions. DOI, [10.5256/f1000research.11027.d158606](https://doi.org/10.5256/f1000research.11027.d158606)<sup>37</sup>

## Author contributions

VV and VN planned and carried out the experiments. VV wrote the manuscript. VV and VN did the data cleaning and statistical analysis, respectively. VV interpreted the data. VV, NK, AJ, RP, GM and LRF conceived the idea of the discussion chapter and proofread the manuscript.

## Competing interests

No competing interests were disclosed.

## Grant information

The author(s) declared that no grants were involved in supporting this work.

## Acknowledgements

We wish to thank the Auckland Cancer Society, University of Auckland, New Zealand for funding the salaries of N.K. and L.R.F.; Maurice Wilkins Centre, University of Auckland for funding the salary of AJ; and Cardiff University for funding the salary of GM. This study is based on what has been reported in the research article by Vaidyanathan *et al* (2017). Therefore contributions made by all authors in the said article are acknowledged.

## References

- Cooperberg MR, Vickers AJ, Broering JM, *et al.*: **Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.** *Cancer*. 2010; **116**(22): 5226–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jemal A, Bray F, Center MM, *et al.*: **Global cancer statistics.** *CA Cancer J Clin*. 2011; **61**(2): 69–90.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Thompson I, Thrasher JB, Aus G, *et al.*: **Guideline for the management of clinically localized prostate cancer: 2007 update.** *J Urol*. 2007; **177**(6): 2106–31.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- D'Amico AV, Whittington R, Kaplan I, *et al.*: **Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4–20 nanograms per milliliter.** *Cancer*. 1998; **82**(2): 334–41.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bratt O: **Hereditary prostate cancer: clinical aspects.** *J Urol*. 2002; **168**(3): 906–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schaid DJ: **The complex genetic epidemiology of prostate cancer.** *Hum Mol Genet*. 2004; **13** Spec No 1: R103–21.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Karunasinghe N, Han DY, Zhu S, *et al.*: **Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand.** *Genes Nutr*. 2012; **7**(2): 179–90.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Karunasinghe N, Lange K, Yeo Han D, *et al.*: **Androgen Pathway Related Gene Variants and Prostate Cancer Association in Auckland Men.** *Curr Pharmacogenomics Person Med*. 2013; **11**(1): 22–30.  
[Publisher Full Text](#)
- Tweardy DJ, Belmont JW: **“Personalizing” academic medicine: opportunities and challenges in implementing genomic profiling.** *Transl Res*. 2009; **154**(6): 288–94.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cordell HJ: **Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans.** *Hum Mol Genet*. 2002; **11**(20): 2463–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hartwig FP: **SNP-SNP Interactions: Focusing on Variable Coding for Complex Models of Epistasis.** *J Genet Syndr Gene Ther*. 2013; **4**: 189.  
[Publisher Full Text](#)
- Su WH, Yao Shugart Y, Chang KP, *et al.*: **How genome-wide SNP-SNP interactions relate to nasopharyngeal carcinoma susceptibility.** *PLoS One*. 2013; **8**(12): e83034.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jamshidi M, Fagerholm R, Khan S, *et al.*: **SNP-SNP interaction analysis of NF- $\kappa$ B signaling pathway on breast cancer survival.** *Oncotarget*. 2015; **6**(35): 37979–94.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tao S, Feng J, Webster T, *et al.*: **Genome-wide two-locus epistasis scans in prostate cancer using two European populations.** *Hum Genet*. 2012; **131**(7): 1225–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hodgson F, Obertova Z, Brown C, *et al.*: **PSA testing in general practice.** *J Prim Health Care*. 2012; **4**(3): 199–204.  
[PubMed Abstract](#)
- Vaidyanathan V, Karunasinghe N, Javed A, *et al.*: **Prostate Cancer: Is It a Battle Lost to Age?** *Geriatrics*. 2016; **1**(4): 27.  
[Publisher Full Text](#)
- Vaidyanathan V, Naidu V, Karunasinghe N, *et al.*: **Dataset 1 in: SNP-SNP interactions as risk factors for aggressive prostate cancer.** *F1000Research*. 2017.  
[Data Source](#)
- Vaidyanathan V, Naidu V, Kao CH, *et al.*: **Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men - a genotypic approach.** *Mol Biosyst*. 2017; **13**(4): 681–98.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Karunasinghe N, Han DY, Goudie M, *et al.*: **Prostate disease risk factors among a New Zealand cohort.** *J Nutrigenet Nutrigenomics*. 2012; **5**(6): 339–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bishop KS, Han DY, Karunasinghe N, *et al.*: **An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer.** *Peer J*. 2016; **1**(4): e1731.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zong GY, Donner A: **The merits of testing Hardy-Weinberg equilibrium in the analysis of unmatched case-control data: a cautionary note.** *Ann Hum Genet*. 2006; **70**(Pt 6): 923–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nampashaki A, Razaghi-Moghadam Z, Ansari-Pour N: **The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies.** *Cell J*. 2015; **17**(2): 187–92.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Purcell S, Neale B, Todd-Brown K, *et al.*: **PLINK: a tool set for whole-genome association and population-based linkage analyses.** *Am J Hum Genet*. 2007; **81**(3): 559–75.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kote-Jarai Z, Olama AA, Giles GG, *et al.*: **Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.** *Nat Genet*. 2011; **43**(8): 785–91.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Holt SK, Kwon EM, Koopmeiners JS, *et al.*: **Vitamin D pathway gene variants and prostate cancer prognosis.** *Prostate*. 2010; **70**(13): 1448–60.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Di Rosa M, Malaguarrera M, Nicoletti F, *et al.*: **Vitamin D3: a helpful immunomodulator.** *Immunology*. 2011; **134**(2): 123–39.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lou YR, Qiao S, Talonpoika R, *et al.*: **The role of Vitamin D<sub>3</sub> metabolism in prostate cancer.** *J Steroid Biochem Mol Biol*. 2004; **92**(4): 317–25.  
[PubMed Abstract](#) | [Publisher Full Text](#)

28. Nair R, Maseeh A: **Vitamin D: The "sunshine" vitamin.** *J Pharmacol Pharmacother.* 2012; **3**(2): 118–26.  
[PubMed Abstract](#) | [Free Full Text](#)
29. Nelen V: **Epidemiology of prostate cancer.** *Recent Results Cancer Res.* 2007; **175**: 1–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
30. **Consensus Statement on Vitamin D and Sun Exposure in New Zealand.** Wellington, New Zealand: Ministry of Health and Cancer Society of New Zealand; 2012.  
[Reference Source](#)
31. Corn PG, Wang F, McKeenan WL, *et al.*: **Targeting fibroblast growth factor pathways in prostate cancer.** *Clin Cancer Res.* 2013; **19**(21): 5856–66.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Emoto H, Tagashira S, Mattei MG, *et al.*: **Structure and expression of human fibroblast growth factor-10.** *J Biol Chem.* 1997; **272**(37): 23191–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Campisi J: **The role of cellular senescence in skin aging.** *J Invest Dermatol Symp Proc.* 1998; **3**(1): 1–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Coppé JP, Desprez PY, Krtolica A, *et al.*: **The senescence-associated secretory phenotype: the dark side of tumor suppression.** *Annu Rev Pathol.* 2010; **5**: 99–118.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Tazi J, Bakkour N, Stamm S: **Alternative splicing and disease.** *Biochim Biophys Acta.* 2009; **1792**(1): 14–26.  
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Zhang Y, Bertolino A, Fazio L, *et al.*: **Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.** *Proc Natl Acad Sci U S A.* 2007; **104**(51): 20552–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Vaidyanathan V, Naidu V, Karunasinghe N, *et al.*: **Dataset 2 in: SNP-SNP interactions as risk factors for aggressive prostate cancer.** *F1000Research.* 2017.  
[Data Source](#)

# Open Peer Review

Current Referee Status:  

Version 1

Referee Report 17 May 2017

doi:10.5256/f1000research.11895.r22808

 **Yog Raj Ahuja , Zeenath Jehan**

Department of Molecular Medicine, Vasavi Medical & Research Centre, Hyderabad, Telangana, India

The authors have carried out SNP genotyping in from a New Zealand cohort of men with self-reported European ethnicity that have been clinically diagnosed with aggressive and non-aggressive PCa, and healthy controls. They have identified a number of SNPs from the GWAS from various European populations and described SNP-SNP interaction as a risk factor for aggressive PCa in a New Zealand cohort. The intronic SNP rs2121875, an on chromosomal position 5p12 near the fibroblast growth factor 10 (*FGF10*) gene<sup>24</sup>, has been identified to be associated with the intronic SNP rs4809960, an intronic SNP present in chromosomal position 20q13 near the gene cytochrome P450 family 24 subfamily A member 1 (*CYP24A1*). The protein encoded by *CYP24A1* initiates the degradation of the physiologically active form of Vitamin D3 (VD3) <sup>26</sup> which is an important hormone that is actively involved in regulating cell proliferation in the prostate, and has also been identified to have increased expression in PCa cell lines. The epistatic effect of the SNP-SNP interactions suggested by the authors may be relevant in view of many recent studies showing intronic mutations which can exert their effect on protein coding exons. The recent observation of decreasing Vitamin D3 levels worldwide further support the role of environmental factors in these gene environment interactions. Future studies may help in understanding the role of SNPs and environmental interactions.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Partly

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Yog Raj Ahuja: Genetics; Zeenath Jehan: Genetics and cancer genomics

**We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 09 May 2017

doi:10.5256/f1000research.11895.r22484



**Syed Muhammad Shahid**

The Karachi Institute of Biotechnology and Genetic Engineering (KIBGE), University of Karachi, Karachi, Pakistan

The manuscript identified a number of SNPs in GWAS as risk factors for PCa in various European populations as well as defined SNP-SNP interactions, using PLINK software, with nucleic acid samples from a New Zealand cohort. The approach which authored used to find a gene x environment marker for aggressive PCa gene x environment interactions can be adjusted statistically, however, it is highly impossible in practicality.

The manuscript compiled most of recent literature available on the subject and propose justified discussion on the research question.

Since I do not have sufficient expertise in statistical analyses used to elaborate the key findings of the manuscript, I am reluctant to comment on the authenticity and validity of conclusion.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

I cannot comment. A qualified statistician is required.

**Are all the source data underlying the results available to ensure full reproducibility?**

Partly

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

-----